RxDoctor Payments Data

Greg Steinbock

Urology · Jeffersonville, INNPI 1972590057

Payments from drug & device makers

What this record shows

The money is spread across several categories — ownership interests (53.4%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Whip Mix Corporation at 53.4% of the total. Reporting peaked in 2022 at $60,986 and has fallen 90.4% since, to $5,843 in 2023. Among urology clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$134,128in general payments, 2019–2025

Across 635 payments — averaging $211.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Whip Mix Corporation$72K
  • Bayer$18K
  • Merck$10K
  • Astellas Pharma US Inc$10K
  • Pfizer$8K
  • Johnson & Johnson$7K
  • plus $10K from 28 others
$43,322in ownership & investment interests, 2019–2025

Across 3 payments — averaging $14,441 each. An ownership or investment interest held by the physician or an immediate family member.

  • Whip Mix Corporation$43K

What the payments were for

  • Consulting fees$20,14415%
  • Speaking & faculty fees$20,40615%
  • Travel & lodging$8,2036%
  • Food & beverage$13,37410%
  • Education$3390%
  • Ownership interest$71,66253%

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,128 in reported general payments places this provider in the 95th percentile of 272 urology providers in Indiana.

See all urology providers in Indiana

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide11$137,970
Tamsulosin Hcl19$221

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BayerNubeqa$17,535$137,97011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 272 urology providers in Indiana.

Other urology in Jeffersonville

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →